News | June 20, 2014

Medical Device by Purdue Engineers Could Standardize Pacemaker Lead Stability Tests

SafePace Purdue University Pacemaker Lead Stability

June 20, 2014 — Cardiac surgeons could use a patent-pending invention by Purdue University engineering students to standardize a test that determines if a pacemaker's leads are securely embedded in heart tissue.

SafePace is a mechanical device that could lower the rate of lead dislodgement of pacemakers, which regulate the beating of the heart by delivering electrical impulses through the leads. Elizabeth Mercer and Johnny Zhang, graduate students in Purdue University's Weldon School of Biomedical Engineering, designed and developed SafePace with Jason Lee and Joseph Pellettiere, then students in Purdue's School of Mechanical Engineering.

Mercer said a dislodged lead could result in overpacing or underpacing of the heart.

"Unnecessarily pacing the heart rapidly decreases the battery life, and if the patients have an implantable cardioverter defibrillator, they may receive accidental shocks," Mercer said. "Insufficient pacing means some of the electric pulses, which save lives, don't occur."

To directly test the mechanical stability of leads, surgeons are encouraged to tug on one end of the lead to gather tactile feedback. The tug test is highly subjective because the amount of force used could vary among procedures and surgeons.

"Surgeons have no tools to provide quality control or assurance that the tug is adequate and consistent across all procedures they perform," Zhang said. "Our mission in developing SafePace is to design a mechanical feedback system that increases a doctor's and patient's confidence in the stability of a pacemaker lead and reduces the probability of a lead being dislodged."

SafePace consists of two components held together through a proprietary coupling mechanism, but pull apart at a force that indicates that the lead is securely implanted.

"After the tip of the pacemaker lead has been implanted into the heart wall, one component of SafePace is attached to the end of the lead not affixed to the heart," Mercer said. "The surgeon grips the second component, then pulls. If SafePace does not separate, the lead will disengage with the heart wall and the surgeon will know it must be implanted again. If it separates into its two components, the surgeon will know the lead is well implanted."

SafePace does not cause any additional harm to the patient, is adaptable to current pacemaker leads, is non-invasive and adds minimal time to the procedure to implant a pacemaker. The Purdue Office of Technology Commercialization has filed applications for U.S. and international patents on the device.

"The next step to develop SafePace is to build a second prototype. We want to incorporate a device that can attach over the stylet, which is the stiffening agent of a pacemaker lead," Zhang said. "More testing is required before SafePace can be commercialized."

A video about SafePace is available at http://youtu.be/YMSs4vFzf48.

For more information: www.purdue.edu/newsroom/releases/2014/Q2/medical-device-by-purdue-engineers-could-standardize-pacemaker-lead-stability-tests.html

Related Content

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Novel Antibiotics Can Help Lower EP Device Infection Rates. Pictured here is an ICD. Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

News | EP Lab | May 17, 2018
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics
The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

News | EP Lab | May 16, 2018
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced
LivaNova Completes Sale of Cardiac Rhythm Management (CRM - electrophysiology) Business to MicroPort Scientific
News | EP Lab | April 30, 2018
April 30, 2018 — LivaNova announced it completed the sale of its cardiac rhythm management (CRM) business to MicroPor
LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Overlay Init